A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial

PURPOSE: Steadily maintaining high intra-gastric PH is the major factor for successful Helicobacter pylori (H.pylori) eradication. It is important to search for a stronger PPI. Dexlansoprazole MR is a dual delayed release formulation PPI taken once daily which is capable of maintaining longer durati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Infect Drug Resist
Autors principals: Tai, Wei-Chen, Liang, Chih-Ming, Bi, Kuo-Wei, Kuo, Chung-Mou, Lu, Lung-Sheng, Wu, Cheng-Kun, Yang, Shih-Cheng, Kuo, Yuan-Hung, Lee, Chen-Hsiang, Huang, Chih-Fang, Hsu, Chien-Ning, Hsu, Pin-I, Wu, Deng-Chyang, Hu, Tsung-Hui, Wu, Keng-Liang, Chuah, Seng-Kee
Format: Artigo
Idioma:Inglês
Publicat: Dove 2019
Matèries:
Clinical Trial Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6754331/
https://ncbi.nlm.nih.gov/pubmed/31571945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S213998
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars